Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1900MR)

This product GTTS-WQ1900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1900MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13760MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ7736MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ10583MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ10400MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ412MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ458MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ11675MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15218MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW